- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 241/08 - Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
Patent holdings for IPC class C07D 241/08
Total number of patents in this class: 374
10-year publication summary
|
33
|
22
|
20
|
15
|
31
|
21
|
23
|
27
|
15
|
15
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| MannKind Corporation | 517 |
47 |
| Massachusetts Institute of Technology | 10102 |
15 |
| Cytokinetics, Inc. | 280 |
9 |
| Suntory Holdings Limited | 2037 |
9 |
| Cv6 Therapeutics (NI) Limited | 32 |
9 |
| Evonik Operations GmbH | 4154 |
8 |
| Promentis Pharmaceuticals, Inc. | 15 |
7 |
| BASF SE | 20979 |
6 |
| New York University | 1755 |
6 |
| Translate bio, Inc. | 416 |
6 |
| Gen1e Lifesciences Inc. | 26 |
6 |
| F. Hoffmann-La Roche AG | 7941 |
5 |
| California Institute of Technology | 3985 |
5 |
| VALO Health, Inc. | 174 |
5 |
| University of Southern California | 2114 |
4 |
| Dong-A Pharmaceutical Co., Ltd. | 80 |
4 |
| Zymergen Inc. | 263 |
4 |
| Merck Sharp & Dohme LLC | 3760 |
4 |
| Boehringer Ingelheim International GmbH | 4642 |
3 |
| Janssen Pharmaceutica N.V. | 3369 |
3 |
| Other owners | 209 |